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Abstract
Background: Neuropathic pain is a complex chronic pain generated by damage to, or pathological
changes in the somatosensory nervous system. Characteristic features of neuropathic pain are
allodynia, hyperalgesia and spontaneous pain. Such abnormalities associated with neuropathic pain
state remain to be a significant clinical problem. However, the neuronal mechanisms underlying the
pathogenesis of neuropathic pain are complex and still poorly understood. Casein kinase 1 is a
serine/threonine protein kinase and has been implicated in a wide range of signaling activities such
as cell differentiation, proliferation, apoptosis, circadian rhythms and membrane transport. In
mammals, the CK1 family consists of seven members (α, β, γ1, γ2, γ3, δ, and ε) with a highly
conserved kinase domain and divergent amino- and carboxy-termini.
Results: Preliminary cDNA microarray analysis revealed that the expression of the casein kinase 1
epsilon (CK1 ) mRNA in the spinal cord of the neuropathic pain-resistant N- type Ca2+ channel
deficient (Cav2.2-/-) mice was decreased by the spinal nerve injury. The same injury exerted no
effects on the expression of CK1  mRNA in the wild-type mice. Western blot analysis of the spinal
cord identified the downregulation of CK1ε protein in the injured Cav2.2-/- mice, which is consistent
with the data of microarray analysis. However, the expression of CK1ε protein was found to be
up-regulated in the spinal cord of injured wild-type mice. Immunocytochemical analysis revealed
that the spinal nerve injury changed the expression profiles of CK1ε protein in the dorsal root
ganglion (DRG) and the spinal cord neurons. Both the percentage of CK1ε-positive neurons and
the expression level of CK1ε protein were increased in DRG and the spinal cord of the neuropathic
mice. These changes were reversed in the spinal cord of the injured Cav2.2-/- mice. Furthermore,
intrathecal administration of a CK1 inhibitor IC261 produced marked anti-allodynic and anti-
hyperalgesic effects on the neuropathic mice. In addition, primary afferent fiber-evoked spinal
excitatory responses in the neuropathic mice were reduced by IC261.
Conclusions: These results suggest that CK1ε plays important physiological roles in neuropathic
pain signaling. Therefore CK1ε is a useful target for analgesic drug development.
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Neuropathic pain is a complex chronic pain generated by
damage to, or pathological changes in the somatosensory
nervous system. Neuropathic pain is characterized by the
appearance of allodynia (pain perceived in response to
normally innocuous stimuli), hyperalgesia (increased
responsiveness to painful stimuli) and spontaneous pain
[1]. Such abnormalities associated with neuropathic pain
state remain to be a significant clinical problem. However,
the neuronal mechanisms underlying the pathogenesis of
neuropathic pain are complex and still poorly understood
[2]. Partly for this reason, attempts to develop new thera-
peutic agents confront difficulties and the efficacies of cur-
rently available drugs for neuropathic pain are reported to
be marginal and/or variable for each patient. Thus, devel-
opment of new strategies leading to pharmacological
treatment of neuropathic pain is eagerly awaited. For this
purpose, it would be essential to understand the molecu-
lar mechanism of the induction and maintenance of neu-
ropathic pain.
In the present study, we have utilized mice lacking N-type
voltage-dependent Ca2+ channels (VDCCs) and searched
for new neuropathic pain-related molecules. These mice
exhibit markedly reduced symptoms of neuropathic pain
after spinal nerve injury [3], suggesting a critical role of N-
type VDCCs (Cav2.2) in the development of neuropathic
pain. It is generally believed that changes of gene expres-
sion induced by nerve injury contribute substantially to
the initiation and maintenance of long lasting neuro-
pathic pain state [4]. Therefore, we have searched for the
genes whose expression was altered by spinal nerve injury
in the wild-type (Cav2.2+/+) and N-type VDCC-deficient
(Cav2.2-/-) spinal cord using microarray techniques and
compared these gene expression profiles. From this pre-
liminary comparative cDNA microarray analysis, we
found that the spinal nerve injury down-regulated the
expression of casein kinase 1 epsilon (CK1 ) mRNA in the
spinal cord of Cav2.2-/- mice but not of the Cav2.2+/+ mice.
CK1 is a serine/threonine protein kinase and has been
implicated in a wide range of signaling activities such as
cell differentiation, proliferation, apoptosis, circadian
rhythms and membrane transport [5-7]. In mammals, the
CK1 family consists of seven members (α, β, γ1, γ2, γ3, δ,
and ε) with a highly conserved kinase domain and diver-
gent amino- and carboxy-termini. CK1 isoforms were
shown to be associated with cytosolic vesicles including
small synaptic vesicles and phosphorylated several small
synaptic vesicle-associated proteins in neuronal cells
[6,8,9]. In the present study, we have tested a possibility
that CK1ε plays a role in the maintenance of neuropathic
pain state. We first quantified the expression of CK1ε pro-
tein and then examined the distribution of this protein in
dorsal root ganglia and the spinal cords. Next, we have
tested the effects of a CK1 inhibitor on neuropathic pain
behaviors. We have also analyzed the effects of the CK1
inhibitor on the excitatory responses in the spinal dorsal
horn elicited either by direct activation of postsynaptic
glutamate receptors or by presynaptic primary afferent
fiber stimulation.
Results
Expression of CK1  in the spinal cord
Using cDNA microarray technique, we previously
reported that the expression of ~900 genes out of ~10,000
genes in the Cav2.2+/+ spinal cord was increased more than
1.20-fold by the lumbar L5 and L6 spinal nerve ligation
(L5/L6 SNL) injury as compared with sham-operated
Cav2.2+/+ mice. Among these genes, we recently suggested
that glucocorticoid receptor [10] and peripheral-type ben-
zodiazepine receptor [11] are useful targets in the man-
agement of neuropathic pain. On the other hand, we also
observed that the expression of ~1,300 genes out of
~10,000 genes was reduced more than 1.20-fold by L5/L6
SNL injury in the Cav2.2-/- spinal cord when compared
with sham-operated Cav2.2-/- mice. Because Cav2.2-/- mice
showed markedly reduced symptoms of the SNL-induced
neuropathic pain [3], we speculated that these down-reg-
ulated genes have some contribution to the reduced neu-
ropathic pain symptoms. Among these down-regulated
genes, we focused on CK1  in this study, because there has
been no information about the expression and function
of this molecule in sensory pathway up to this moment,
in spite of the fact that CK1 is one of the first serine/thre-
onine protein kinases that were isolated and characterized
[5]. The expression of CK1  mRNA was not changed in
Cav2.2+/+ mice (1.01-fold) but decreased by 2.81-fold in
Cav2.2-/- mice 2 weeks after SNL injury. Quantitative real-
time PCR analysis of C57BL/6J mice 2-3 weeks after sham
or SNL operation also showed no difference of the CK1
mRNA expression in the spinal cord (n = 4 for sham and
SNL, data not shown).
We next examined the expression of CK1ε protein in the
spinal cord by immunoblot analyses (Figure 1A and 1B).
The CK1ε expression was significantly enhanced in the
Cav2.2+/+ spinal cord 2 weeks after SNL injury. In contrast,
CK1ε expression in the SNL-operated Cav2.2-/- spinal cord
was significantly reduced, which is consistent with the
cDNA microarray results.
Immunohistochemical analysis of CK1  expression in the 
spinal cord after spinal nerve injury
We further characterized the distribution of CK1ε-positive
cells in the spinal cord of sham and neuropathic mice by
immunofluorescence techniques. As shown in Figure 1C-
E, the CK1ε protein was found to be broadly expressed in
the spinal cord.
Consistent with the immunoblot data, the intensity of
CK1ε-immunoreactivity (CK1ε-IR) in the dorsal horn ofPage 2 of 14
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nerve injury.
To further characterize the localization profile of the
CK1ε, we performed double staining of CK1ε with cell-
type specific markers. CK1ε-IR was colocalized with a neu-
ronal marker, neuronal specific nuclear protein (NeuN)
(Figure 2Ai-Ci), but not with an astorocytic marker, glial
fibrillary acid protein (GFAP) (Figure 2Aii-Cii) or a micro-
glial marker, ionized calcium binding adaptor molecule 1
(Iba 1) (Figure 2Aiii-Ciii). Both GFAP and Iba 1 immu-
nostainings were significantly enhanced on the side ipsi-
lateral to SNL injury (Figure 2Bii, Biii, D and 2E), a finding
consistent with the literature [12,13]. Intriguingly, SNL-
induced enhancements of GFAP- and Iba 1-IR were mark-
edly suppressed in Cav2.2-/- mice (Figure 2Cii, 2Ciii, 2D
and 2E). On the other hand, we found SNL injury did not
affect the number of NeuN-positive cells in spinal dorsal
horn both in wild-type and Cav2.2-/- mice.
Double staining experiments also revealed that the CK1ε
was expressed in 71% (superficial layer) and 66% (middle
layer) of the neurons in the L5 dorsal horn of sham-oper-
ated spinal cord (Figure 3A and 3B). Two weeks after SNL
injury, the percentage was increased to 87% and 75%
(superficial and middle layers, respectively) in the L5 dor-
sal horn ipsilateral to the injury (Figure 3A and 3B) with-
out significant changes in the contralateral side (data not
shown). In Cav2.2-/- spinal cord, SNL injury, in contrast,
significantly reduced the percentage of the CK1ε-positive
neurons in both ipsilateral superficial and middle layers
(Figure 3A and 3B). There were no overt differences in the
numbers between right and left sides in naive control and
between ipsilateral and contralateral sides in sham-oper-
ated animals (data not shown).
Although the increase of CK1ε-positive neurons after SNL
injury would explain the upregulation of CK1ε protein
revealed by the immunoblot experiments, we also tested
another possibility that SNL injury increased the expres-
sion level of CK1ε protein in the dorsal horn neurons.
Confocal microscopic analyses indicated that the expres-
sion of CK1ε protein was indeed up-regulated in the ipsi-
lateral superficial dorsal horn neurons of C57BL/6J mice
2 weeks after SNL injury, whereas the same injury slightly
reduced the CK1ε expression in Cav2.2-/- spinal cord (Fig-
ure 3C-F). CK1ε-IR was detected mostly in the cytoplasm,
with only faint staining in the nucleus.
Immunohistochemical analysis of CK1  expression in the 
dorsal root ganglia after spinal nerve injury
To further address the feature of CK1ε expression at neu-
ropathic pain state, we have investigated whether CK1ε is
expressed in primary sensory neurons and whether the
expression pattern of CK1ε is altered by the SNL injury by
immunofluorescence analyses. In agreement with the pre-
vious reports [14-16], we observed marked loss (50%) of
ipsilateral L5 DRG neurons 2 weeks after the nerve injury
when compared with the ipsilateral side of sham operated
mice (Table 1). Most dramatic decrease (87%) was
observed in large-sized group, and 53% and 38% losses
were observed in small- and medium-sized groups,
respectively (Table 1). Similar level of cell loss was also
observed in SNL-operated Cav2.2-/- mice (Table 1).
In L5 DRG, the CK1ε-IR was mainly observed in small-
and medium-sized neurons with IR appearing largely in
cytoplasm with weak staining in the nucleus (Figure 4).
The percentages of CK1ε-positive neurons ipsilateral to
sham operation were 68.4%, 29.1% and 15.1% in small-,
medium- and large-sized neurons, respectively (Figure
4D). The percentages of CK1ε-positive neurons in the
DRG ipsilateral to sham operation were similar to those in
contralateral to sham operation and SNL injury, and in
naive DRG (data not shown). On the other hand, signifi-
cant increases in the percentages of CK1ε-positive neurons
in the ipsilateral L5 DRG compared with sham group were
observed in all size groups 2 weeks after SNL injury (Fig-
ure 4B and 4D). Similar changes of CK1ε-positive cell
population were also observed in SNL-operated Cav2.2-/-
mice (Figure 4C and 4D). Expression level of CK1ε pro-
tein was also analyzed by a computerized image analysis
SNL upregulates CK1ε expression in the spinal cordFigure 1
SNL upregulates CK1ε expression in the spinal cord. 
(A) Immunoblot performed with a rabbit polyclonal anti-
CK1ε antibody in the Cav2.2+/+ and Cav2.2-/- spinal cord. L5/L6 
segments ipsilateral to the surgery were used. (B) Expression 
of CK1ε protein, which is normalized by GAPDH loading 
control. *p < 0.05, SNL Cav2.2+/+ compared with sham 
Cav2.2+/+ (Student's t test), # p < 0.05, SNL Cav2.2-/- com-
pared with sham Cav2.2-/- (Student's t test); n = 7 in each 
group. (C-E) Immunofluorescent micrographs of CK1ε-IR in 
L5 spinal cord from sham- (C) and SNL-operated (D) C57BL/
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significant increases in the intensity of CK1ε-IR were
observed in the small- and medium-sized neurons of ipsi-
lateral L5 DRG 2 weeks after SNL injury.
Similar extent of increase was also observed in SNL-oper-
ated Cav2.2-/- mice (Figure 4E). In contrast, the intensity of
CK1ε-IR in large-sized neurons was not significantly
changed following SNL injury. To clarify the expression
profiles of CK1ε protein in sham and neuropathic mice L5
DRGs, we carried out the double immunofluorescence
analysis using CK1ε antibodies together with antibodies
against two DRG neuron markers. Small and medium-
sized DRG neurons were generally classified into two sub-
groups, which have been designated as peptidergic and
non-pepetidergic [17]. The former expresses two major
Immunohistochemical analysis of the L5 spinal cord sectionFigure 2
Immunohistochemical analysis of the L5 spinal cord section. (A-C) Immunofluorescent micrographs of CK1ε (red) in 
L5 spinal cord ipsilateral to sham- (A), SNL- (B) operated C57BL/6J mice, and SNL-operated Cav2.2-/- mice (C) co-labeled with 
NeuN (Ai-Ci), GFAP (Aii-Cii) or Iba 1(Aiii-Ciii) shown in green. Scale bar, 100 μm. (D, E) Mean number of GFAP-positive spi-
nal astrocyte (D) and Iba 1-positive microglia (E). Mouse antibody against CK1ε was used in Aiii-Ciii and rabbit antibody against 
CK1ε was used in Ai-Ci and Aii-Cii. There was always a tendency that the intensity with the mouse monoclonal antibody is 
generally stronger and the background is relatively higher than with the rabbit polyclonal antibody, although the specificity of 
staining was found to be similar between the two antibodies. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA followed by 
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gene-related peptide (CGRP), and the latter expresses iso-
lectin B4 (IB4)-binding glycoprotein. CK1ε protein was
found in both CGRP- and IB4-positive populations (Fig-
ure 5). The CK1ε expression was detected in 66.4% of
CGRP-positive neurons and 44.9% of CK1ε-positive neu-
rons were CGRP-positive in sham operated DRG neurons
(Figure 5). Similarly, the CK1ε expression was detected in
82.3% of IB4-positive neurons and 38.3% of CK1ε-posi-
tive neurons were IB4-positive. Similar results were also
obtained from naive DRG neurons (data not shown). Two
weeks after SNL, a marked decrease of IB4 binding (both
the cell number and the intensity) was observed in ipsilat-
eral L5 DRGs (Figure 5D), which is similar to that shown
by a previous study [16]. Relatively lesser extent of
decrease occurred in the number and the intensity of
CGRP-positive small- and medium sized neurons (Figure
5B). In injured DRG neurons, CK1ε-IR was detected in
94% and 91% of CGRP- and IB4-positive neurons, respec-
tively. CGRP-IR was detected in 65% of CK1ε-positive
neurons, however, IB4 binding was observed in only 3%
of CK1ε-positive neurons. The proportions of CK1ε-
expressing cells within CGRP- and IB4-positive neurons in
the contralateral DRGs were not different from those of
naive and sham-operated DRGs (data not shown). The
colocalization of CK1ε with CGRP observed in the super-
ficial dorsal horn area of spinal cord slice preparations
(Figure 5E and 5F) suggest that part of the CK1ε protein
detected by immunoblot analyses (Figure 1A and 1B) and
CK1ε-IR in the spinal cord (Figure 1D) originated from
the CK1ε present at the primary afferent fibers and termi-
nals, because CGRP is generally accepted as a pure pri-
mary afferent marker [18]. It seems clear that the intensity
of CK1ε protein in the primary afferent fibers and termi-
nals is enhanced in CGRP-positive DRG neurons after
SNL injury (Figure 5F). Because enhanced protein expres-
sion of CK1ε was observed in DRG neurons, we have ana-
lyzed mRNA level by quantitative real-time PCR method
and found that the 2.03 fold increase of CK1ε mRNA was
observed 2 weeks after SNL operation (n = 4 for sham and
SNL, p < 0.001, data not shown).
Effect of SNL injury on the number of CK1ε-positive neurons and CK1ε-IRFigure 3
Effect of SNL injury on the number of CK1ε-positive 
neurons and CK1ε-IR. (A, B) Percentage of CK1ε-positive 
neurons in the superficial (A) and middle (B) layers of the 
dorsal horn. NeuN-positive cells were regarded as neurons. 
Each value represents the mean ± SEM of 3-4 determina-
tions. *p < 0.05, ***p < 0.001 (one-way ANOVA followed by 
Tukey's post hoc test). (C-E) Confocal photomicrographs of 
CK1ε expression in the superficial dorsal horn neurons from 
sham- (C) and SNL- (D) operated C57BL/6J mice, and SNL-
operated Cav2.2-/- mice (E). Scale bar, 10 μm. (F) Averaged 
intensities of CK1ε-IR in the superficial dorsal horn. *p < 
0.05, ***p < 0.001 (one-way ANOVA followed by Tukey's 












































































Table 1: Number of L5 ipsilateral DRG neurons 2 weeks after L5 and L6 spinal nerve injury.
Small-sized Medium-sized Large-sized Total
Sham C57BL/6J 371.6 ± 31.2 116.2 ± 10.7 18.6 ± 2.90 506.3 ± 42.3
SNL C57BL/6J 176.2 ± 18.4*** 72.3 ± 6.64** 2.33 ± 0.59*** 250.8 ± 21.9***
SNL Cav2.2-/- mutant 225.3 ± 25.2*** 67.7 ± 8.62** 3.17 ± 0.72*** 296.1 ± 30.2***
Each value represents the mean ± SEM (n = 12 in each group). **p < 0.01, ***p < 0.001, compared with Sham C57BL/6J (one-way ANOVA followed 
by Tukey's post hoc test). Numbers were obtained using conventional profile counting methods.Page 5 of 14
(page number not for citation purposes)
Molecular Pain 2009, 5:74 http://www.molecularpain.com/content/5/1/74Intrathecal injection of a CK1 inhibitor attenuated 
neuropathic pain behaviors
To investigate whether the up-regulation of CK1ε protein
is involved in the maintenance of neuropathic pain, we
next examined the effects of a CK1 inhibitor IC261 [19].
I.t. injections of IC261 (0.1-1 nmol) dose-dependently
increased both withdrawal threshold and withdrawal
latency of the hind paw ipsilateral to SNL (Figure 6).
Another CK1 inhibitor CKI-7 [20] also showed similar
effects (data not shown). These results suggest that block-
ing the CK1ε activity at the spinal level is effective in
reducing mechanical allodynia and thermal hyperalgesia.
The maximum effects were observed 0.5-1 h after the
injection of IC261 and significant analgesic effects on
both mechanical allodynia and thermal hyperalgesia were
still observed 3-4 h after the injection of the highest doses
used in this study (Figure 6A and 6B). IC261 had no sig-
nificant effects on the contralateral hind paw (Figure 6A
and 6B).
Intrathecal injection of saline or dimethyl sulfoxide
(DMSO; 3% in saline) used as a solvent for the drugs did
not show any effects on mechanical allodynia and ther-
mal hyperalgesia (Figure 6C and 6D).
CK1 inhibitor reduced presynaptic primary afferent fiber-
evoked spinal excitatory responses
To explore the mechanism of CK1 inhibitor-induced anal-
gesia at the spinal level, we made L5 dorsal root attached-
spinal cord slice preparation from adult mice (9-12 weeks
old) and carried out spatio-temporal analyses of the pri-
mary afferent fiber-evoked excitatory responses in the dor-
sal horn by means of imaging techniques using a voltage-
sensitive dye 4-(2-(6-(dibutylamino)-2-naphthale-
nyl)ethenyl)-1-(3-sulfopropyl)-pyridinium hydroxide
(di-4-ANEPPS). Repetitive stimulation (10 pulses at 20
Hz) of L5 dorsal root produced prolonged (lasting for 3-4
s) and widely propagating excitatory responses extending
from superficial layer to deeper laminae within the ipsilat-
eral L5 spinal dorsal horn (Figure 7). In sham and SNL
animals, the magnitude of integrated area of the optical
response recorded in the superficial layer of each animal
group were significantly larger than those recorded in the
corresponding middle layer (Figure 7). Remarkably, the
optical responses were not reduced by SNL injury (Figure
7Ci and 7Di), in spite of the fact that 50% of the neurons
were lost in DRG. Excitatory synaptic transmission evoked
by primary afferents is known to be mainly mediated by
glutamate [18,21], and glutamate receptors, especially
NMDA receptor, are considered to play important roles in
development and maintenance of neuropathic pain
[22,23]. Application of an NMDA-receptor antagonist, D-
APV (50 μM), suppressed the optical responses in the
superficial and middle layers elicited by the nerve stimu-
lation in sham and SNL animals. A perfusion of a solution
containing both D-APV (50 μM) and a non-NMDA-recep-
tor antagonist, CNQX (20 μM), further reduced the opti-
cal responses in both layers in sham and SNL animals
(Figure 7). These results suggest that the activation of
glutamate receptors is largely responsible for the induc-
tion of the excitatory responses evoked by the repetitive
electrical stimulation of the primary afferents. To identify
a role of CK1ε in neuropathic pain-related spinal nocice-
ptive transmission, we investigated the effects of the CK1
inhibitor on the dorsal root-evoke optical responses (Fig-
ure 8). IC261 (1 and 2 μM) showed significant inhibitory
effects on the optical responses in the SNL dorsal horn
(Figure 8B and 8D). Similar results were obtained when
using another CK1 inhibitor CKI-7 (data not shown).
Interestingly, IC261 did not reduce the dorsal root-evoked
optical responses elicited in the dorsal horn of sham mice
(Figure 8A and 8C). Vehicle control (0.01 and 0.03%
CK1ε expression in the DRG neurons after spinal nerve injuryFigur  4
CK1ε expression in the DRG neurons after spinal 
nerve injury. (A-C) Immunofluorescent micrographs show-
ing CK1ε-positive neurons in L5 DRG sections from sham- 
(A) and SNL- (B) operated C57BL/6J mice, and SNL-oper-
ated Cav2.2-/- mice (C). Scale bar, 50 μm. (D, E) Percentages 
(D) and immunofuorescence intensities (E) of CK1ε-positive 
neurons in the DRGs. DRG neurons were divided into small-
sized (< 600 μm2), medium-sized (600-1200 μm2), and large-
sized (> 1200 μm2) groups based on their cross-sectional 
areas. *p < 0.05, ***p < 0.001 (one-way ANOVA followed by 
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evoked in both superficial and middle layers of naive dor-
sal horn (data not shown). Thus CK1 inhibitor was found
to be effective in reducing spinal excitatory response elic-
ited by the presynaptic electrical stimulation only in neu-
ropathic mice.
CK1 inhibitor reduced direct NMDA-evoked excitatory 
responses
To test whether the observed effects of CK1 inhibitor orig-
inated from the direct effects on the postsynaptic gluta-
mate receptors, we further examined the effect of IC261
on the optical responses induced by NMDA and gluta-
mate in the SNL spinal cord in the presence of tetrodo-
toxin (TTX; 0.3 μM).
In both superficial and middle layer of the SNL spinal
cord, excitatory optical responses evoked by the bath-
application of NMDA (300 μM) for 30 s was not inhibited
by 1 μM of IC261 but significantly inhibited by 3 μM of
IC261 (Figure 9A). These results suggest that blockade of
primary afferent fiber-evoked excitatory responses in the
dorsal horn by IC261 (Figure 8B and 8D) was partly
caused by the blockade of NMDA evoked responses,
because only higher concentration of IC261 was effective.
On the other hand, 3 μM of IC261 did not show any effect
on the excitatory optical responses evoked by the bath-
application of glutamate (3 mM) for 1 min (Figure 9B).
Discussion
CK1 family constitutes one of the eight major groups of
protein kinases in the human and mouse genome [24,25].
However, few physiological roles have been described for
CK1 in synaptic transmission. It has been recently
reported that metabotoropic glutamate receptors down-
regulated NMDA receptor-mediated synaptic currents
through CK1 dependent activation of protein phos-
phatases in the striatum [26]. In the present study, we
have shown several lines of evidence that CK1ε plays a key
role in the maintenance of neuropathic pain induced by
spinal nerve injury. Thus, CK1 isoforms expressed in cen-
tral and peripheral nervous system might display region-
and individual cell-specific regulation of synaptic trans-
mission in normal and pathological states.
To our knowledge, this is the first report demonstrating
the alteration of the expression pattern of CK1ε in the spi-
nal cord and DRG following spinal nerve injury. After spi-
nal nerve injury, number of CK1ε-positive neurons and
the expression level of CK1ε protein were both increased
in the superficial and middle layers of ipsilateral L5 dorsal
horn. These SNL-induced changes observed in wild-type
mice were completely reversed in Cav2.2-/- mice. Further-
more NMDA-evoked excitatory responses and neuro-
pathic pain behaviors were inhibited by IC261. These
findings may point the importance of CK1ε-positive neu-
rons within the spinal dorsal horn in neuropathic pain
state.
We also found that enhanced GFAP expression possibly
reflecting astroglial activation and enhanced Iba 1 expres-
sion possibly reflecting microglial migration identified in
L5 spinal dorsal horn from neuropathic mice were
strongly suppressed in SNL-operated Cav2.2-/- mice. The
reason why the glial activation accompanying spinal
injury is suppressed in Cav2.2-/- mice is not known at this
moment, but this seems to be a reason why Cav2.2-/- mice
did not show neuropathic pain symptoms after SNL,
because these glial activations have been shown to induce
neuropathic pain [12,13]. It would be interesting to
explore the mechanism by which N-type Ca2+ channel
activation induced by the SNL injury leads to enhanced
CK1ε expression in the spinal neuron and glial activation
at the spinal dorsal horn in the future study. One plausi-
ble mechanism for the enhanced CK1ε expression would
be that CK1ε expression may be regulated directly or indi-
rectly by the calcium entry through N-type Ca2+ channel
both at the transcriptional and at the translational levels.
The calcium dependent transcriptional regulation may
include up-regulation of CK1ε mRNA and some miRNAs
regulating the translation of CK1ε. If the SNL injury down
regulates some of the gene expression including CK1ε
besides the activation of N-type Ca2+ channel, mRNA level
may not be changed in Cav2.2+/+ mice but will be reduced
in Cav2.2-/- mice. Furthermore, if the activation of Cav2.2
channel induces translation of CK1ε by the up-regulated
regulatory miRNAs or other unknown mechanism, pro-
tein level will be increased in Cav2.2+/+ mice but will be
Expression of CK1ε in subpopulations of the DRG neuronsFigure 5
Expression of CK1ε in subpopulations of the DRG 
neurons. (A-D) Immunofluorescent micrographs of L5 DRG 
sections labelled with CK1ε-IR (red) together with CGRP or 
IB4 (green) in sham- (A, C) and SNL- (B, D) operated C57BL/
6J mice. (E, F) Confocal images of the spinal cord sections 
labeled with the antibody against CK1ε together with the 
antibody against CGRP. In the spinal cord, CK1ε (red) is 
partly colocalized with CGRP (green), a marker for primary 
afferents, in the superficial dorsal horn in sham- (E) and SNL- 
(F) operated mice. Scale bars, 20 μm.
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exactly what we observed in the actual experiments. How-
ever these results are based on the several assumptions
that have to be proven experimentally. Furthermore,
expression levels of mRNA and protein in DRGs were
found to be proportional. Thus further rigorous study
would be necessary to clarify the role of N-type Ca2+ chan-
nel on the expression of CK1ε.
The effects of nerve injury on the number of DRG neurons
have been examined in many different injury models.
Although the degree varies in each model presumably due
to the differences of the experimental manipulations and
the counting methodologies, previous studies in rat [14-
16,27] and mouse [28] indicate a loss of neurons in L5
DRG after spinal nerve injury. Our results were found to
be consistent with these previous reports. More impor-
tantly, we found that both the percentage of CK1ε-posi-
tive neurons and the expression level of CK1ε protein
were significantly increased in ipsilateral small- and
medium-sized L5 DRG neurons after SNL. Furthermore
intense expression of CK1ε was found in the primary
afferent fibers possibly including presynaptic boutons
after SNL injury. These enhanced expression and follow-
ing activation of CK1ε may be responsible for the appar-
ently normal level of spinal excitatory responses in SNL
mice in spite of the fact that more than 50% of the DRG
neurons were lost after SNL injury.
Small- and medium-sized DRG neurons are generally con-
sidered to correspond to C- and Aδ-fiber neurons, whose
axons terminate in the superficial layer of the dorsal horn.
On the other hand, large-sized DRG neurons are generally
considered to correspond to Aβ-fiber neurons, whose
Effects of CK1 inhibitor IC261 on SNL-induced neuropathic pain behaviorsFigure 6
Effects of CK1 inhibitor IC261 on SNL-induced neuropathic pain behaviors. (A, B) Effects of intrathecal injection of 
IC261 on mechanical allodynia (A) and thermal hyperalgesia (B). (C, D) Effects of intrathecal injection of 3% DMSO used for 
dissolving IC261 on mechanical allodynia (C) and thermal hyperalgesia (D). Paw withdrawal threshold to mechanical stimulation 
and paw withdrawal latency to thermal stimuli are plotted against the time after intrathecal injection of IC261 or DMSO. Data 
are mean ± SEM (n = 6-13). *p < 0.05, ***p < 0.001, compared with pre-drug (at 0 h) data (one-way ANOVA followed by Dun-
nett's post hoc test). C57BL/6J mice two weeks after SNL injury were used.
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Molecular Pain 2009, 5:74 http://www.molecularpain.com/content/5/1/74axons terminate in the middle layer of the dorsal horn.
Compensation of excitatory responses in the superficial
layer of SNL-dorsal horn may be caused by the facilitation
of nociceptive transmitter release from the CK1ε-positive
C- and Aδ-fiber terminals. In contrast, since the cell loss of
large-sized DRG neurons are prominent, the compensa-
tion of excitatory responses observed at the middle layer
of SNL-dorsal horn may be caused by the indirect effect
from the enhanced excitation of superficial layer by the
increased input through interneurons linking laminae I-II
and laminae III-IV neurons. However, further rigorous
study is necessary to verify this hypothesis.
On the other hand, the nature of apparently recovered spi-
nal excitatory responses seems to be very different from
those found in normal animals. Firstly, CK1 inhibitor had
no effect on the excitatory responses in sham-operated
mice but SNL injury turned CK1 inhibitor effective in
blocking excitatory responses. Secondly, CK1 inhibitor is
effective in blocking neuropathic pain in injured hindpaw
Primary afferent fiber-evoked spinal excitatory responses in the spinal dorsal hornFigure 7
Primary afferent fiber-evoked spinal excitatory responses in the spinal dorsal horn. (A, B) Optical responses taken 
before and after the addition of glutamate receptor antagonists (D-APV 50 μM alone or D-APV 50 μM + CNQX 20 μM) in the 
perfusion solution for 30 min, and also after a wash of the antagonists. The L5 dorsal root (ipsilateral to sham- or SNL-opera-
tion) attached to a transverse slice of sham- (A) or SNL- (B) operated spinal cord was stimulated by a suction electrode. 
Repetitive stimulation with a high intensity (1 mA, 1 ms current pulses, at 20 Hz for 0.5 s as indicated by the bars) was used to 
activate both A and C fibers. (C, D) Effects of ionotoropic glutamate receptor antagonists on the dorsal root-evoked excita-
tory responses recorded in the ipsilateral superficial (Ai, Bi, C) and middle (Aii, Bii, D) layers of dorsal horn. Summary of 
results, testing the effects of an NMDA-receptor antagonist D-APV (Cii, Dii) and mixture of D-APV and a non-NMDA recep-
tor antagonist CNQX (Ciii, Diii) on the optical response elicited by the dorsal root stimulation. Optical responses were also 
recorded before drug application (Ci, Di) and after washout of the drugs (Civ, Div). The percentage compared to pre-drug 
response (as 100%) was shown as % control. ###p < 0.001, compared with corresponding middle layer response (Student's t 
test). n = 16 and 19 for sham and SNL spinal cord slices, respectively. (Cii-Civ, Dii-Div) *p < 0.05, **p < 0.01, ***p < 0.001, 
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hindpaw. Naturally, it is important to identify the target
proteins of CK1ε that would induce these changes. Our
preliminary experiments trying to identify CK1ε targets
resulted in many candidate proteins (data not shown).
Further rigorous study is necessary to narrow down and
identify the causative proteins.
Conclusions
The present study demonstrated that SNL injury enhanced
the expression of CK1ε protein in spinal dorsal horn and
DRG neurons. Furthermore CK1 inhibitor was found to
be effective in blocking excitatory synaptic responses in
the spinal dorsal horn and neuropathic pain symptoms.
These results suggest that CK1ε plays important physio-
logical roles in neuropathic pain signaling, which makes
it a useful target for analgesic drug development.
Methods
Animals
Male C57BL/6J mice (7-8 weeks old at the time of opera-
tion) were purchased from Clea Japan, Inc. (Tokyo,
Japan) and housed under controlled temperature (24 ±
1°C) and humidity (55 ± 10%) with a 12-h light-dark
cycle with food and water freely available. Experiments
were conducted with the approval of the Animal Care
Committee of Tokyo Medical and Dental University
(approval No. 0090173), and according to the ethical
guidelines for the study of experimental pain in conscious
animals published by the International Association of the
Study of Pain [29].
Animal model of neuropathic pain
L5/L6 SNL was carried out as described previously [3,10].
Intrathecal injection
I.t. injection was given in a volume of 5 μl by percutane-
ous puncture through an intervertebral space at the level
of the 5th or 6th lumbar vertebra, according to a previ-
ously reported procedure [30,31].
Behavioral studies
Behavioral studies were conducted in a sound proof room
during the light cycle (8:00 a.m.-8:00 p.m.) 2-4 weeks
after spinal nerve ligation as described [32]. An investiga-
tor, who was unaware of the drug treatment, performed
all of the behavioral experiments.
cDNA microarray analysis
Cav2.2-/- mice were generated and housed as previously
reported [3]. Seven Cav2.2+/+ and Cav2.2-/- mice were used
for L5/L6 SNL surgery and five Cav2.2+/+ and Cav2.2-/- mice
Effects of IC261 on the primary afferent fiber-evoked spinal excitatory responsesFigure 8
Effects of IC261 on the primary afferent fiber-evoked spinal excitatory responses. (A, B) Effects of IC261 on the 
dorsal root-evoked optical responses were assessed in the sham- (A) and SNL- (B) operated mice. Optical responses were 
taken before (black lines) and after the addition of IC261 (1 and 2 μM) in the perfusion solution for 30 min (red and green lines, 
respectively). Ipsilateral superficial (Ai, Bi) and middle dorsal horn (Aii, Bii) were analyzed. (C, D) Summary of results, testing 
the effects of IC261 on sham- and SNL-operated mice in superficial (Ci, Di) and middle dorsal horn (Cii, Dii). n = 6 and 11 for 
sham and SNL slices, respectively. The percentage compared to pre-drug response (as 100%) was shown as % control. **p < 
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was performed using the CodeLink™ UniSet Mouse 10K I
(GE Healthcare, Piscataway, NJ) following the protocol
provided by the manufacturer. Four data sets (Cav2.2+/+
sham, Cav2.2+/+ SNL, Cav2.2-/- sham, Cav2.2-/- SNL) were
compared using the CodeLink™ System Software.
Immunoblot anaysis
Proteins were separated by SDS-PAGE (7.5% gel) and
then transferred to a polyvinylidene difluoride membrane
(Millipore, Billerica, MA). Anti-CK1ε antibody was used
(rabbit; 1: 1000; Santa Cruz Biotechnology, Santa Cruz,
CA). We have also tested other anti-CK1ε antibody
(mouse; 1: 500; BD Transduction Laboratories, Franklin
Lakes, NJ) and found that they showed similar results
(single band with same size in immunoblot analysis, data
not shown). Immunoreactivity was detected by using the
ECL system (GE Healthcare, Buckinghamshire, UK). An
anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody (mouse, 1:20,000; Chemicon, Temec-
ula, CA) was used to normalize protein loading. Relative
intensities of the bands were quantified by using an image
analysis system with Image J software, version 1.40 g
(National Institutes of Health, Bethesda, MD).
Immunohistochemistry
Transverse spinal and DRG sections (10 μm) were used.
The antibodies used are as follows: CK1ε (rabbit, 1:50;
Santa Cruz Biotechnology; mouse, 1:50; BD Transduction
Laboratories), CGRP (rabbit, 1:1000; Sigma), NeuN
(mouse, 1:100; Chemicon), GFAP (mouse, 1:400; Chemi-
con) and Iba 1 (rabbit, 1:500, Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan). The sections were then
incubated for 2 h at room temperature with Alexa Fluor
488-labeled donkey anti-rabbit IgG (1:1000; Invitrogen,
Paisley, UK) or Cy3-conjugated donkey anti-mouse IgG
(1:1000; Jackson ImmunoResearch, West Grove, PA). For
the detection of IB4 binding, biotinylated IB4 (1:400; Vec-
tor Laboratories, Burlingame, CA) and FITC-conjugated
extravidin (1:500; Sigma) were used. Sections of a set of
control and experimental tissues were concurrently
immunostained and images were captured under the
same conditions. Control tissue sections, in which the pri-
mary antibody was omitted, showed no specific staining.
The experiments were carried out at least three times.
Immunofluorescent preparations were examined with a
fluorescence microscope (BIOREVO BZ-9000; Keyence
Corp, Osaka, Japan).
Effects of IC261 on NMDA- and glutamate- evoked excitatory responses in the spinal dorsal hornFigure 9
Effects of IC261 on NMDA- and glutamate- evoked excitatory responses in the spinal dorsal horn. (A, B) Optical 
responses taken before (black lines) and after the addition of IC261 (1 and 3 μM, red and green lines, respectively) in the per-
fusion solution containing TTX (0.3 μM) for 30 min. NMDA- or glutamate-evoked responses were elicited by the perfusion of 
300 μM of NMDA for 30 sec (A) or 3 mM glutamate for 1 min (B) (shown as bars). Optical responses were recorded from 
both superficial (Ai, Bi) and middle (Aii, Bii) layers of dorsal horns ipsilateral to SNL. (C, D) Summary of the results, testing the 
effects of IC261 (1 μM, n = 5; 3 μM, n = 9) on the NMDA-evoked responses and IC261 (3 μM; n = 4) on the glutamate-evoked 
responses. The percentage compared to pre-drug response (as 100%) was shown as % control. *p < 0.05, ***p < 0.001, com-
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L5 DRGs. On average, five to seven non-adjacent sections
of each DRG, where the CK1ε-positive neurons with visi-
ble nuclei were equally distributed throughout the rostro-
caudal length of the DRG, were randomly selected from 3
to 4 animals in naive control, sham- and SNL-operated
groups and numbers of neurons that showed distinctive
CK1ε-labeling compared with background labeling were
counted as CK1ε-positive by two investigators blinded to
the surgical treatment and averaged. The fluorescence
intensity was quantified using a 255-level gray scale [33].
To determine the percentage of immunoreactive neurons
in each DRG, a threshold of average fluorescence intensity
level (for example, 30 in 255-level gray scale for CK1ε)
was set by observing several images of normal DRGs. The
fluorescence intensity threshold was then applied to all
other sections of ipsilateral and contralateral DRGs. The
fluorescence intensity and cross-sectional area of CK1ε-
positive neurons were quantified using BZ-II analyzer
(BZ-H1C software; Keyence Corp, Osaka, Japan). To dis-
tinguish cell size-specific changes, we divided the DRG
neurons into small-sized (< 600 μm2), medium-sized
(600-1200 μm2), and large-sized (> 1200 μm2) groups
based on their cross-sectional areas [34,35]. For the co-
localization analyses, double stained DRG sections were
similarly selected from 3-4 mice, and CK1ε-, CGRP- and
IB4-positive cells were counted.
For counting the dorsal horn cells, five to seven sections
from the L5 spinal cord segment were randomly selected
from each mouse and numbers of distinctive CK1ε-, Neu
N-, GFAP- and Iba 1-positive cells in the superficial and
middle layers of the dorsal horn were counted by two
investigators blinded to the surgical treatment and aver-
aged. The border between superficial and middle layers
was delineated according to a representative immunos-
taining images of protein kinase C type γ (PKCγ) prepared
in our laboratory. PKCγ is present in a subpopulation of
neurons in the inner part of lamina II and allows a good
localization of the border between laminae II and III. The
middle layer was defined as dorsal half of deep dorsal
horn (laminae III-VI). The number of cells per one section
was averaged in each naive control, sham- and SNL-oper-
ated animal and the overall means were calculated.
Proportions of CK1ε-positive cells and intensities of
CK1ε-IR measured in single- and double-staining were
not significantly different in any of the experimental
groups. Therefore, data from both single- and double-
labeled cells were combined.
Confocal laser-scanning microscopy
Images of spinal cords stained with the rabbit anti-CK1ε
antibody or double labeled with CK1ε (mouse) and
CGRP (rabbit) antibodies were collected using a Zeiss
LSM 5 Pascal confocal microscope with argon and helium
neon lasers (Carl Zeiss Microscopy, Jena, Germany). A ×
63, 1.2 NA water-immersion C-apochromatic objective
and 2 × zoom value were used for high magnification. The
digital images of 20 consecutive z-scan sections (step size
approximately 0.5 μm) were analyzed on a computer
equipped with an image analysis system (Image J version
1.40 g). CK1ε-IR was quantified using a 255-level gray
scale [33]. To quantify CK1ε-IR of the superficial dorsal
horn neurons, the immunofluorecence intensities of five
randomly selected neurons were quantified using a 255-
level gray scale. For each spinal cord section, the ratio of
the immunofluorescence intensities of the ipsilateral to
the contralateral side was calculated. The ratios for 3-4
non-adjacent sections were averaged in sham- and SNL-
operated groups.
Preparation of spinal cord slices
Spinal cord slices were prepared according to the method
described previously [21,36]. Transverse slices (thickness,
600-750 μm) of the L5 spinal segments with the L5 dorsal
root attached were prepared and stained with a fluores-
cent voltage-sensitive dye di-4-ANEPPS (Invitrogen).
Optical recording
Changes in voltage-sensitive dye fluorescence in the spi-
nal cord were detected using an optical recording system
MiCAM02 (Brainvision Inc., Tsukuba, Japan) [37,38].
Repetitive electrical stimulation (current: 1.0 mA, dura-
tion: 1 ms) comprised of 10 pulses at 20 Hz were applied
through a suction electrode attached to the dorsal root, as
described previously [39,40] to induce a long-lasting exci-
tatory component including NMDA receptor transmis-
sion. Both A- and C-fibers were thought to be activated by
the stimulation mode [41]. For the recording of glutamate
receptor agonist-evoked responses in the presence of TTX
(0.3 μM), short exposure mode of MiCAM02 recoding
and analyzing software (BV analyzer; Brainvision Inc.,
Tsukuba, Japan) was used to minimize dye bleaching
according to the manufacturer's guide. The effect of a
pharmacological agent on the nerve- or glutamate recep-
tor agonist-induced responses was evaluated by compar-
ing the averaged magnitude of two or three control
responses with the magnitude of response after 25-30 min
equilibration for each drug. The concentrations of gluta-
mate receptor antagonists and TTX used were determined
according to the previous studies [40,42,43] and our pre-
liminary study.
Drugs
D-APV, CNQX and IC261 were purchased from Tocris
Bioscience, Bristol, UK. Glutamate and NMDA were from
Sigma, St. Louis, MO, USA. TTX was from Sankyo Co.,
Ltd., Tokyo, Japan.Page 12 of 14
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Molecular Pain 2009, 5:74 http://www.molecularpain.com/content/5/1/74Statistical analysis
Experimental data are expressed as mean ± SEM. Single
comparisons were made using Student's two-tailed paired
or unpaired t-test. One-way ANOVA followed by the Dun-
nett's or Tukey's test was used for multiple comparisons. p
< 0.05 was considered statistically significant.
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